Palisade Bio Secures Funding Through Warrant Exercises
Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company in the clinical stage, specializes in innovative treatments for autoimmune, inflammatory, and fibrotic diseases. The Company recently made headlines by entering into agreements with several accredited investors to exercise existing warrants, resulting in an impressive $3.9 million funding boost.
Details of the Warrant Exercise
In total, the Company’s agreement revolves around the exercise of warrants permitting the purchase of up to 4,318,905 shares of common stock. These warrants, which featured adjusted exercise prices of $1.40, were initially issued on May 10, 2022, February 1, 2024, May 6, 2024, and December 13, 2024. Notably, each exercise will occur at a reduced price of $0.9047 per share, allowing for increased investment capacity.
Placement Agent Involvement
The transaction witnessed the expertise of Ladenburg Thalmann & Co. Inc. acting as the exclusive placement agent, ensuring a smooth process for both the investors and the Company.
Intended Use of Proceeds
The anticipated gross proceeds from the warrant exercises are projected at around $3.9 million prior to any deductions for placement agent fees and related offering costs. A significant portion of these funds is earmarked for working capital and general corporate purposes. This allocation will empower Palisade to continue its mission of providing innovative therapies to patients in need.
Replacement Warrants Offered
The investors who exercise their existing warrants for cash will receive new, unregistered warrants termed the “Replacement Warrants.” These warrants will be eligible for purchase of common stock in a private placement under Section 4(a)(2) of the Securities Act of 1933. Collectively, these new warrants may allow the purchase of an additional 8,637,810 shares at an exercise price of $0.9047 per share, with a five-year exercise term from shareholder approval.
Registered Securities and Compliance
Importantly, the shares entitled to be issued upon the exercise of these Existing Warrants are registered through registration statements that have received the Securities and Exchange Commission's approval. However, the Replacement Warrants and the shares obtained through their exercise have not been registered yet, limiting transactions to accredited investors only.
The Path Forward
Palisade Bio has committed to filing a registration statement with the SEC for the resale of shares from the Replacement Warrants. Such proactive steps reflect the Company’s dedication to transparency and regulatory compliance, which is vital for fostering investor confidence.
About Palisade Bio
Palisade Bio is committed to revolutionizing therapeutics aimed at addressing autoimmune, inflammatory, and fibrotic diseases. By maintaining a targeted approach in their development of innovative therapeutics, Palisade aims to create significant advancements in patient care and treatment modalities. For further information, visit their official website at www.palisadebio.com.
Frequently Asked Questions
What is the amount raised through the warrant exercise?
The Company raised approximately $3.9 million from the exercise of existing warrants.
What will the raised funds be used for?
The net proceeds will be used for working capital and general corporate purposes to support ongoing operations.
Who acted as the placement agent in this transaction?
Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for the transaction.
What are Replacement Warrants?
Replacement Warrants are new unregistered warrants received by holders upon exercising their existing warrants for cash, allowing them to purchase additional shares at a specified price.
Where can I find more information about Palisade Bio?
More information can be found on the Company’s official website, which is www.palisadebio.com.
